NYSE:ALife Sciences
Agilent Technologies (A) Is Up 5.4% After New OPDIVO-Linked PD-L1 Test Approval - Has The Bull Case Changed?
In July 2026, Agilent Technologies received U.S. FDA approval for its PD-L1 IHC 28-8 pharmDx assay as a companion diagnostic to identify patients with several gastric and esophageal cancers who may be eligible for Bristol Myers Squibb’s OPDIVO and OPDIVO QVANTIG immunotherapies, for use exclusively on the Agilent Autostainer Link 48 platform.
This decision deepens Agilent’s role in oncology testing by tying its assay and staining system directly to established immunotherapy regimens in...